Mallinckrodt Illegal Drug Monopoly What investors Need to Know
Mallinckrodt (MNK) stock rated Strong Sell at stock market LIVE.TV since $85 should constitute a hard lesson for all those investors who believe in Wall Street crooks upgrading shares ahead of a crash.
An investment plan to make millions of dollars in the stock market shared with subscribers to the world’s best service for small investors – live markets premium.
Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the Federal Trade Commission said on Wednesday.
Mallinckrodt’s share price dropped sharply to just under $43 from above $49 on a report Wednesday, which proved incorrect, that the FTC would sue Mallinckrodt. It spiked above $50 after news of a settlement and closed at $46.53, down 5.8 percent.
In 2001, Questcor bought the rights to Acthar, a type of hormone-based drug used to treat infantile spasms as well as multiple sclerosis. Over time, the company raised the price from $40 per vial to more than $34,000, the FTC said. Questcor was acquired by Mallinckrodt in 2014.
Acthar, which is off patent, represented 34 percent of Mallinckrodt’s $3.4 billion in net sales for fiscal 2016, the company said in a government filing.
Per patient, Medicare spent more on Acthar than for any other drug in 2015, putting out $504 million for just 3,104 patients, according to the Medicare Drug Spending Dashboard.
Several U.S. drug makers have been criticized for sharp increases in drugs, notably Turing Pharmaceuticals’ Daraprim and Mylan’s EpiPen. The U.S. Centers for Medicare and Medicaid Services reported 11 drugs saw price increases of more than 100 percent in 2015.
“This is an egregious case of a monopolist doing a deal to eliminate potential competition and keep its power over pricing. It is abhorrent that lifesaving drugs cost New Yorkers tens of thousands of dollars,” said Attorney General Eric Schneiderman in a statement.
Mallinckrodt, an Irish company headquartered in the United Kingdom, said the settlement would not affect its net sales and slammed the FTC’s probe.
What investors should be looking for going forward?
We remind subscribers that Mallinckrodt has been a core component of your portfolio in Live markets premium with a clear initial defined objective aiming at a crash
Having said this, Mallinckrodt (MNK) has been upgraded from Strong Sell $85 to neutral $44 for technical reasons only – please refer to the chart for your guidance going forward.
Hereafter, if Mallinckrodt (MNK) is unable to bounce back above the previous support range $54-58 breaking it to the upside in high volume may spell trouble for a considerable period of time for this company. Meanwhile, we cannot suggest to one buying to hold Mallinckrodt shares since this vehicle is considered to be highly speculative.
Our downside remains $38. Investors might wish to use the crash to trim existing short positions on shares leaving a trailing stop for the remaining position according to resistance range mentioned in this article
Lastly, concerning short term trading the fact that shares were halted yesterday opening at $51 was used to sell short Mallinckrodt intraday down to $46 twice which has resulted into dramatic profits. Volatility is likely to remain high.
For those who did not believe that Mallinckrodt shares could collapse you have been learning a tremendous lesson. Hopefully you will not forget about it for the rest of your life. But hey, that’s entirely investors concern since the company is not going to introduce new stock picks just because some fools keep missing Vieira’s uncanny vision!
I ‘m very pleased to see that a crash occurred in every biotech company I referred to, i.e. traders’ have had a lifetime investing opportunity to become millionaires at least 40 times.
NEWS: World’s best trader sells Mallinckrodt shares downgrading to Strong Sell calling a crash